[1] Mackenzie PI, Owens IS, Burchell B, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence[J]. Pharmacogenetics,1997,7(4):255-269. [2] Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily[J]. Pharmacogenet Genomics, 2005,15(10):677-685. [3] Lehmann JM, Mckee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions[J]. J Clin Invest,1998,102(5):1016-1023. [4] Xu C, Li CY, Kong AN,et al. Induction of phase I, II and III drug metabolism/transport by xenobiotics[J]. Arch Pharm Res,2005,28(3):249-268. [5] Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy[J]. Drug Resist Updat, 2003, 6(2):71-84. [6] Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism[J]. Clin Pharmacol Ther,1996,59(5):491-502. [7] TanabeM, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR-1) gene[J]. J Pharmacol Exp Ther, 2001, 297(3): 1137-1143. [8] Banerjee S, Li Y, Wang Z, et al. Multi-targeted therapy of cancer by genistein[J]. Cancer Lett, 2008,269(2):228-242. [9] Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity[J]. Pharmacogenetics, 2001, 11(3): 217-221. [10] Chen C, Zhou J, Ji C. Quercetin: A potential drug to reverse multidrug resistance[J]. Life Sciences, 2010,87(11/12):333-338. [11] 张松波,段娟,闾四平,等.天然维生素E对CYP3A4活性影响的体内研究[J].中国临床药理学与治疗学,2010,15(8):911-915. |